Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 60/100

Failure Rate

12.5%

1 terminated/withdrawn out of 8 trials

Success Rate

83.3%

-3.2% vs industry average

Late-Stage Pipeline

13%

1 trials in Phase 3/4

Results Transparency

20%

1 of 5 completed trials have results

Key Signals

1 with results

Enrollment Performance

Analytics

Phase 2

4(57.1%)

Phase 1

2(28.6%)

Phase 3

1(14.3%)

7Total

Phase 2(4)

Phase 1(2)

Phase 3(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (8)

Showing 8 of 8 trials

NCT03613181Phase 3Unknown

ANG1005 in Leptomeningeal Disease From Breast Cancer

Role: lead

NCT01967810Phase 2Completed

ANG1005 in Patients With Recurrent High-Grade Glioma

Role: lead

NCT02048059Phase 2Completed

ANG1005 in Breast Cancer Patients With Recurrent Brain Metastases

Role: lead

NCT01497665Phase 2Terminated

GRN1005 in Non-Small Cell Lung Cancer (NSCLC) Patients With Brain Metastases (GRABM-L)

Role: lead

NCT01480583Phase 2Completed

GRN1005 Alone or in Combination With Trastuzumab in Breast Cancer Patients With Brain Metastases

Role: lead

NCT02755987Unknown

Expanded Access to ANG1005 for Individual Patients

Role: lead

NCT00539383Phase 1Completed

A Phase 1, Open-Label, Dose Escalation Study of ANG1005 in Patients With Advanced Solid Tumors and Metastatic Brain Cancer

Role: lead

NCT00539344Phase 1Completed

A Phase 1, Open-Label, Dose Escalation Study of ANG1005 in Patients With Malignant Glioma

Role: lead

All 8 trials loaded